EP Patent

EP2575821A4 — BILIARY ACID RECYCLING INHIBITORS AND SATIOGENS FOR THE TREATMENT OF DIABETES, OBESITY AND GASTROINTESTINAL INFLAMMATORY CONDITIONS

Assigned to Satiogen Pharmaceuticals Inc · Expires 2013-12-11 · 12y expired

What this patent protects

Patent listed against maralixibat-chloride.

Drugs covered by this patent

maralixibat-chloride (MARALIXIBAT CHLORIDE)

Patent Metadata

Patent number: EP2575821A4
Jurisdiction: EP
Classification: —
Expires: 2013-12-11
Drug substance claim: No
Drug product claim: No
Assignee: Satiogen Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.